In-silico Studies and Biological Activity of Potential BACE-1 Inhibitors

Arya, Richa; Paliwal, Sarvesh; Gupta, Satya P.; Sharma, Swapnil; Madan, Kirtika; Mishra, Abha; Verma, Kanika; Chauhan, Neha

doi:10.2174/1386207323999200918151331

Cited by 1 publication

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ligand library was created for the identified drug in Autodock version 4.0 (Autodock vina) and the grid batch docking was also performed. In total ten poses were positioned for analysis of type of interaction ( Leechalsit et al., 2019 ; Arya et al., 2021 ; Kesar et al., 2020 ).…”

Section: Methodsmentioning

confidence: 99%

Simvastatin ameliorates oxidative stress levels in HepG2 cells and hyperlipidemic rats

Verma

Makwana

Paliwal

et al. 2022

Current Research in Pharmacology and Drug Discovery

Self Cite

View full text Add to dashboard Cite

Simvastatin is an established anti-hyperlipidemic drug and few studies have indicated its role in the mitigation of oxidative stress. However, a systematic study considering molecular binding/interaction of simvastatin with anti-oxidant enzymes followed by confirmational in vitro and in vivo studies have never been done. We investigated the molecular binding of simvastatin with multiple anti-oxidant enzymes and assessed their levels after the treatment of simvastatin in vitro and in vivo . This study is the first to show the molecular binding of simvastatin to catalase through molecular docking analysis. Moreover, the anti-oxidative properties of simvastatin have not been studied in Lipopolysaccharide (LPS) induced oxidative stress in HepG2 cells. We found that simvastatin effectively attenuated oxidative stress in LPS induced HepG2 cells and high-fat diet (HFD) fed hyperlipidemic rats by increasing the levels of antioxidant enzymes. The activity of catalase and superoxide dismutase (SOD) both increased significantly in oxidatively stressed HepG2 cells after the treatment with simvastatin (10 μM, 24 h). In addition to this, he original cell morphology of oxidatively stressed cells was restored by simvastatin, and an increase in antioxidant enzymes, catalase (0.08 U/cells to 0.12 U/cells), and SOD (0.57 U/cells to 0.74 U/cells) was also noted in HepG2 cells. Furthermore, a significant increase in the antioxidant enzymes such as Catalase, SOD, and reduced glutathione (GSH) was noted after simvastatin treatment in the HFD model. Moreover, we also observed degradation of by-products of lipid peroxidation thiobarbituric acid reactive substances (TBARs), nitric oxide (NO), and protein carbonyl levels. This indicates that simvastatin enhances anti-oxidant enzyme activities and can be repurposed for the treatment of oxidative stress in liver diseases in humans after extensive clinical trials.

show abstract

Section: Methodsmentioning

confidence: 99%